Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

ダウンロード数 : ? 件

この文献の参照には次のURLをご利用ください : https://ir.lib.shimane-u.ac.jp/53573

言語	英語
著者	木下芳一 Sakurai Yuuichi Takeda Development Center Japan, Takeda Pharmaceutical Company Ltd, Osaka, Japan Shiino Madoka Takeda Development Center Japan, Takeda Pharmaceutical Company Ltd, Osaka, Japan Kudou Kentaro Takeda Development Center Japan, Takeda Pharmaceutical Company Ltd, Osaka, Japan Nishimura Akira Takeda Development Center Japan, Takeda Pharmaceutical Company Ltd, Osaka, Japan Miyagi Takuya Department of Gastroenterology and Hepatology, Yao Municipal Hospital, Yao, Japan Iwakiri Katsuhiko Department of Gastroenterology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan Umegaki Eiji Department of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan Ashida Kiyoshi Department of Gastroenterology, Rakuwakai Otowa Hospital, Kyoto, Japan
主題	gastroesophageal reflux; heartburn; NERD; nonerosive gastroesophageal reflux disease; potassium-competitive acid blockers; vonoprazan
掲載誌名	CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
巻	81-82
開始ページ	1
終了ページ	7
ISSN	0011-393X
ISSN（Online）	1879-0313
発行日	2016
DOI	10.1016/j.curtheres.2016.12.001
PubMed ID	28119763
出版者	ELSEVIER SCIENCE INC
資料タイプ	学術雑誌論文
部局	医学部
備考	This work was supported by Takeda Pharmaceutical Company Limited, manufacturer / licensee of vonoprazan. Medical writing assistance was provided by Elise Magatova, PhD, and Tania Dickson, PhD, of ProScribe - Envision Pharma Group, and was funded by Takeda Pharmaceutical Company Limited. ProScribe's services complied with international guidelines for Good Publication Practice (GPP3).